Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling

Ehsan Malek, Megan Herr, James Driscoll, Paul Wallace, Marco Davila, Brian Betts, Shernan Holtan, Hamza Hassan, Theresa Hahn, Han Yu

Blood (2025) 146 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2025-3935

Published: 2025

Journal Articles

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Janine Joseph, Joseph Tario, Han Yu, Sarah Parker, Ian Lund, Kristina Slemmer, Hailey Battaglia, Megan Schaefer, Kimberly Celotto, Philip McCarthy, Hamza Hassan, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2025-1411

Published: 2025

Journal Articles

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Muhammad Salman Faisal, Nour Nassour, Sean Glenn, Han Yu, Sarah Parker, Hamza Hassan, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7484.

https://doi.org/10.1182/blood-2025-7484

Published: 2025

Journal Articles

Circulating immune profile in patients with amyloidosis

Janine Joseph, Joseph Tario, Han Yu, Philip McCarthy, Hamza Hassan, Sarah Parker, Megan Schaefer, Hailey Battaglia, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 5748.

https://doi.org/10.1182/blood-2025-5748

Published: 2025

Journal Articles

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.

Rahul Thakur, Han Yu, Mariam Haji, Vaishali Deenadayalan, Vasanthan Kumarasamy, Ajinkya Buradkar, Jordan Scott, Grant Schofield, Dorothy Pan, Matthew Cortese, Francisco Hernandez-Ilizaliturri, Alex Niu

Blood (2025) 146 (Supplement 1): 3685.

https://doi.org/10.1182/blood-2025-3685

Published: 2025

Journal Articles

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study

Han-Yu Cao, Fangtong Liu, Kai-Wen Tan, Zi-Hao Wang, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Mei-Jing Liu, Zhen Yao, Zheng Li, Ming-Zhu Xu, Hai-Xia Zhou, Haiping Dai, Shengli Xue

Blood (2025) 146 (Supplement 1): 5202.

https://doi.org/10.1182/blood-2025-5202

Published: 2025

Journal Articles

Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation

Sawyer Bawek, Matthew Burwinkel, Nisha Nair, Lacey Yuan, Hillary Jacobson, Han Yu, Theresa Hahn, Jens Hillengass, Megan Herr

Blood (2025) 146 (Supplement 1): 5798.

https://doi.org/10.1182/blood-2025-5798

Published: 2025

Journal Articles

Racial and ethnic disparities in the risk of second primary malignancies among diffuse large B-cell lymphoma survivors in the United States

Pragati Advani, Han Yu, Kayla Catalfamo, Pallawi Torka

Blood (2025) 146 (Supplement 1): 6260.

https://doi.org/10.1182/blood-2025-6260

Published: 2025

Journal Articles

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Zihao Wang, Shuai-Shuai Ge, Miao Wang, Haiping Dai, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2024-197933

Published: 2024

Journal Articles

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Si-Man Huang, Tong-Tong Zhang, Lan Dai, Chao-Ling Wan, Han-Yu Cao, Hai-Ping Dai, Ming-Zhu Xu, Depei Wu, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2024-204660

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Esraa Abdalla, Malak Alharbi, Sawyer Bawek, Catherine Forbes, Ian Lund, Han Yu, Berthliz Durand, Jens Hillengass, Hamza Hassan, Eugene Przespolewski

Blood (2024) 144 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2024-206022

Published: 2024

Journal Articles

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

Ehsan Malek, Marco Davila, Hector Tirado, Shernan G. Holtan, Brian Betts, Han Yu

Blood (2024) 144 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2024-200893

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Fangtong Liu, Chao-Ling Wan, Yu-Qing Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zihao Wang, Sheng-Li Xue, Haiping Dai

Blood (2024) 144 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2024-202500

Published: 2024

Journal Articles

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, Xiao-Hui Hu, Bing Wu, Li Yang, Li Wang, Yang Zhang, De-Pei Wu, Hai-Ping Dai, Hao Zhang, Shengli Xue

Blood (2023) 142 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2023-179733

Published: 2023

Journal Articles

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

Jordan Scott, Samantha Poblete, Jared Vega, Amanda C. Przespolewski, James E Thompson, Elizabeth A. Griffiths, Pamela Jeannette Sung, Steven Green, Han Yu, Michael Shenal, Eugene Przespolewski, Eunice S. Wang, Jeffrey Baron

Blood (2023) 142 (Supplement 1): 5891.

https://doi.org/10.1182/blood-2023-181332

Published: 2023

Journal Articles

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Tong-Tong Zhang, Kai-Wen Tan, Yan Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Songbai Liu, Qiao-Cheng Qiu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2023-185390

Published: 2023

Journal Articles

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Mark G. Faber, Jeffrey Baron, Han Yu, Hassan Awada, Tara L. Cronin, James E. Thompson, Amanda Przespolewski, Steven D. Green, Pamela J. Sung, Elizabeth A. Griffiths, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 9010–9012.

https://doi.org/10.1182/blood-2022-164707

Published: 2022

Journal Articles

Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma

Alina Varabyeva, Jens Hillengass, Wenyan Ji, Han Yu, McKenna Butler, Eugene Przespolewski

Blood (2021) 138 (Supplement 1): 1643.

https://doi.org/10.1182/blood-2021-151182

Published: 2021

Journal Articles

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Amro Elshoury, Han Yu, Wenyan Ji, James E. Thompson, Elizabeth A. Griffiths, Amanda Przespolewski, Steven Daniel Green, Pamela J. Sung, Sheeba baAqeel, Hassan Awada, Eunice S. Wang, Peter A. Kouides

Blood (2021) 138 (Supplement 1): 3637.

https://doi.org/10.1182/blood-2021-146384

Published: 2021

Journal Articles

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Smith Giri, MBBS, Madan R Aryal, MD, Han Yu, PhD, Alyssa Grimshaw, MSLIS, Ranjan Pathak, MD, Scott F. Huntington, MD MPH, Binod Dhakal, MBBS

Blood (2019) 134 (Supplement_1): 2188.

https://doi.org/10.1182/blood-2019-130389

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Circulating immune profile in patients with amyloidosis

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study

Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation

Racial and ethnic disparities in the risk of second primary malignancies among diffuse large B-cell lymphoma survivors in the United States

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only